已收盤 02-06 16:00:00 美东时间
+0.240
+1.67%
Hikma Pharmaceuticals (HKMPY) may have attracted takeover speculation. Shares of Hikma rose as much as 8.8% in London trading. The identity of the company interested in Hikma (HKMPY) is unclear, accor...
02-05 00:47
An announcement from Viatris ( ($VTRS) ) is now available. On February 3, 2026,...
02-04 06:18
Viatris Inc. hat eine Aktualisierung ihres Finanzkalenders veröffentlicht Viatris Inc. wird am 26. Februar 2026 die Finanzzahlen für das vierte Quartal und das Gesamtjahr 2025 veröffentlichen. Das Unternehmen veranstaltet am selben Tag um 8:30 Uhr ET eine Telefonkonferenz, bei der die Ergebnisse von
02-04 05:34
Viatris Inc. publishes update to financial calendar Viatris Inc. will report its fourth quarter and full year 2025 financial results on February 26, 2026. Company executives will host a webcast to discuss the results at 8:30 a.m. ET on the same date. The live webcast will be available at investor.vi
02-04 05:34
Viatris Names Matthew J. Maletta Chief Legal Officer Viatris Inc. has appointed Matthew J. Maletta as Chief Legal Officer, effective February 9, 2026. He succeeds Brian Roman, who will remain as an advisor through April 1, 2026, to support the transition. Maletta brings nearly 30 years of legal expe
02-03 21:30
Viatris Inc's (NYSE:VTRS) short interest as a percent of float has fallen 21.58...
01-30 04:00
今日重点评级关注:Piper Sandler:维持Praxis Precision Medicine"超配"评级,目标价从450美元升至1200美元;Tigress Financial:维持Main International ETF"买入"评级,目标价从52美元升至66美元
01-29 11:06
Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $9 to $12.
01-28 22:13
今日重点评级关注:Guggenheim:维持MBX Biosciences"买入"评级,目标价从77美元升至88美元;摩根士丹利:维持DraftKings"超配"评级,目标价从50美元升至53美元
01-20 10:26
Argus Research upgrades Viatris (NASDAQ:VTRS) from Hold to Buy and announces $15 price target.
01-16 21:44